enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) shares shot up 14.2% during mid-day trading on Friday . The company traded as high as $2.50 and last traded at $2.50. 620 shares were traded during mid-day trading, a decline of 95% from the average session volume of 11,437 shares. The stock had previously closed at $2.19.
enGene Stock Performance
The company’s 50-day moving average is $1.62 and its 200-day moving average is $1.07.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
- Five stocks we like better than enGene
- How to invest in marijuana stocks in 7 steps
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Conference Calls and Individual Investors
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- What is a Death Cross in Stocks?
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
-corp-logo-1200x675.jpg?v=20231005103726&h=45&w=95&zc=2){kind=logo}
